Original Research

HbA_1c Change in Patients With and Without Gaps in Pharmacist Visits at a Safety-Net Resident Physician Primary Care Clinic

Journal of Clinical Outcomes Management. 2021 May;28(3):112-121 | 10.12788/jcom.0046

References

1. Manolakis PG, Skelton JB. Pharmacists’ contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers. Am J Pharm Educ. 2010;74(10):S7.

2. Scott MA, Hitch B, Ray L, Colvin G. Integration of pharmacists into a patient-centered medical home. J Am Pharm Assoc (2003). 2011;51(2):161‐166.

3. Wong SL, Barner JC, Sucic K, et al. Integration of pharmacists into patient-centered medical homes in federally qualified health centers in Texas. J Am Pharm Assoc (2003). 2017;57(3):375‐381.

4. Sapp ECH, Francis SM, Hincapie AL. Implementation of pharmacist-driven comprehensive medication management as part of an interdisciplinary team in primary care physicians’ offices. Am J Accountable Care. 2020;8(1):8-11.

5. Cowart K, Olson K. Impact of pharmacist care provision in value-based care settings: How are we measuring value-added services? J Am Pharm Assoc (2003). 2019;59(1):125-128.

6. Centers for Disease Control and Prevention. Pharmacy: Collaborative Practice Agreements to Enable Drug Therapy Management. January 16, 2018. Accessed April 17, 2021. https://www.cdc.gov/dhdsp/pubs/guides/best-practices/pharmacist-cdtm.htm

7. Choe HM, Farris KB, Stevenson JG, et al. Patient-centered medical home: developing, expanding, and sustaining a role for pharmacists. Am J Health Syst Pharm. 2012;69(12):1063-1071.

8. Coe AB, Choe HM. Pharmacists supporting population health in patient-centered medical homes. Am J Health Syst Pharm. 2017;74(18):1461-1466.

9. Luder HR, Shannon P, Kirby J, Frede SM. Community pharmacist collaboration with a patient-centered medical home: establishment of a patient-centered medical neighborhood and payment model. J Am Pharm Assoc (2003). 2018;58(1):44-50.

10. Matzke GR, Moczygemba LR, Williams KJ, et al. Impact of a pharmacist–physician collaborative care model on patient outcomes and health services utilization. 10.05Am J Health Syst Pharm. 2018;75(14):1039-1047.

11. Aneese NJ, Halalau A, Muench S, et al. Impact of a pharmacist-managed diabetes clinic on quality measures. Am J Manag Care. 2018;24(4 Spec No.):SP116-SP119.

12. Prudencio J, Cutler T, Roberts S, et al. The effect of clinical 10.05pharmacist-led comprehensive medication management on chronic disease state goal attainment in a patient-centered medical home. J Manag Care Spec Pharm. 2018;24(5):423-429.

13. Edwards HD, Webb RD, Scheid DC, et al. A pharmacist visit improves diabetes standards in a patient-centered medical home (PCMH). Am J Med Qual. 2012;27(6) 529-534.

14. Ullah S, Rajan S, Liu T, et al. Why do patients miss their appointments at primary care clinics? J Fam Med Dis Prev. 2018;4:090.

15. Moore CG, Wilson-Witherspoon P, Probst JC. Time and money: effects of no-shows at a family practice residency clinic. Fam Med. 2001;33(7):522-527.

16. Kheirkhah P, Feng Q, Travis LM, et al. Prevalence, predictors and economic consequences of no-shows. BMC Health Serv Res. 2016;16:13.

17. Little RR, Rohlfing C. The long and winding road to optimal HbA10.05_1c10.05 measurement. Clin Chim Acta. 2013;418:63-71.

18. Hill J, Nielsen M, Fox MH. Understanding the social factors that contribute to diabetes: a means to informing health care and social policies for the chronically ill. Perm J. 2013;17(2):67-72.

19. Gonzalez-Zacarias AA, Mavarez-Martinez A, Arias-Morales CE, et al. Impact of demographic, socioeconomic, and psychological factors on glycemic self-management in adults with type 2 diabetes mellitus. Front Public Health. 2016;4:195.

20. Pantalone KM, Misra-Hebert AD, Hobbs TD, et al. The probability of A1c goal attainment in patients with uncontrolled type 2 diabetes in a large integrated delivery system: a prediction model. Diabetes Care. 2020;43:1910-1919.

Study design

This is a retrospective study describing the HbA_1c changes in a patient group that maintained pharmacist visits, with each interval less than 3 months, and in another group, who had a history of a 3-month or longer gap between pharmacist visits. The data were obtained from patients’ electronic medical records during the study period of October 1, 2018, and September 30, 2019, and collected using a HIPAA-compliant, electronic data storage website, REDCap. The institutional review board approval was obtained under HS-19-00929. Patients 18 years and older who were referred by primary care resident physicians for diabetes management, and had 2 or more visits with a pharmacist within the study period, were included. Patients were excluded if they had only 1 HbA_1c drawn during the study period, were referred to a pharmacist for reasons other than diabetes management, were concurrently managed by an endocrinologist, had only 1 visit with a pharmacist, or had no visits with their primary care resident physician for over a year. The patients were then divided into 2 groups: continuous care cohort (CCC) and gap in care cohort (GCC). Both face-to-face and phone visits were counted as pharmacist visits for each group.

Outcomes

The primary outcome was the change in HbA_1c from baseline between the 2 groups. Baseline HbA_1c was considered as the HbA_1c value obtained within 3 months prior to, or within 1 month, of the first visit with the pharmacist during the study period. The final HbA_1c was considered the value measured within 1 month of, or 3 months after, the patient’s last visit with the pharmacist during the study period.

Several subgroup analyses were conducted to examine the relationship between HbA_1c and each group. Among patients whose baseline HbA_1c was ≥ 8%, we looked at the percentage of patients reaching HbA_1c < 8%, the percentage of patients showing any level of improvement in HbA_1c, and the change in HbA_1c for each group. We also looked at the percentage of patients with baseline HbA_1c < 8% maintaining the level throughout the study period and the change in HbA_1c for each group. Additionally, we looked at health care utilization, which included pharmacist visits, primary care physician visits, emergency room and urgent care visits, and hospitalizations for each group. The latter 3 types of utilization were grouped as acute care utilization and further analyzed for visit reasons, which were subsequently categorized as diabetes related and non-diabetes related. The diabetes related reasons linking to acute care utilization were defined as any episodes related to hypoglycemia, diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), foot ulcers, retinopathy, and osteomyelitis infection. All other reasons leading to acute care utilization were categorized as non-diabetes related.

Statistical analysis

Descriptive analyses were conducted using the Mann-Whitney test for continuous data and χ² (or Fisher exact) test for categorical data. A basic difference-in-differences (D-I-D) method was used to compare the changes of HbA_1c between the CCC and GCC over 2 time points: baseline and final measurements. The repeated measures ANOVA was used for analyzing D-I-D. P < .05 was considered significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

Results

Baseline data

A total of 1272 patients were identified within the study period, and 189 met the study inclusion criteria. The CCC included 132 patients, the GCC 57. The mean age of patients in both groups was similar at 57 years old (P = .39). Most patients had Medicaid as their primary insurance. About one-third of patients in each group experienced clinical atherosclerotic cardiovascular disease, and about 12% overall had chronic kidney disease stage 3 and higher. The average number of days that patients were under pharmacist care during the study period was longer in the GCC compared to the CCC, and it was statistically significant (P < .001) (Table 2). The mean ± SD baseline HbA_1c for the CCC and GCC was 10.0% ± 2.0% and 9.9% ± 1.7%, respectively, and the difference was not statistically significant (P = .93). About 86% of patients in the CCC and 90% in the GCC had a baseline HbA_1c of ≥ 8%.